Aquestive Therapeutics, Inc. Interest Expense
Aquestive Therapeutics, Inc. (AQST) reported Interest Expense of $2.78 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-06.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-08-06
- Aquestive Therapeutics, Inc. interest expense for the quarter ending 2024-06-30 was $2.78M, a 102.40% increase year-over-year.
- Aquestive Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $2.78M, a 94.01% increase year-over-year.
- Aquestive Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $2.27M, a 37.76% increase year-over-year.
- Aquestive Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $1.26M, a 23.83% decline year-over-year.
- Aquestive Therapeutics, Inc. interest expense for fiscal 2023 was $6.34M, a 3.28% decline from fiscal 2022.
- Aquestive Therapeutics, Inc. interest expense for fiscal 2022 was $6.55M, a 34.80% decline from fiscal 2021.
- Aquestive Therapeutics, Inc. interest expense for fiscal 2021 was $10.05M, a 9.17% decline from fiscal 2020.
- Aquestive Therapeutics, Inc. interest expense for fiscal 2020 was $11.06M, a 18.74% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|---|
| 2024-06-30 | $2.78M 10-Q · filed 2024-08-06 | $5.56M 10-Q · filed 2024-08-06 | $7.84M derived: sum of 3 quarters · filed 2024-08-06 | $9.09M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2024-03-31 | $2.78M 10-Q · filed 2024-05-07 | $5.06M derived: sum of 2 quarters · filed 2024-05-07 | $6.31M derived: sum of 3 quarters · filed 2024-05-07 | $7.69M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $3.53M derived: sum of 2 quarters · filed 2024-03-05 | $4.90M derived: sum of 3 quarters · filed 2024-08-06 | $6.34M 10-K · filed 2024-03-05 | |
| 2023-09-30 | $1.26M 10-Q · filed 2023-11-06 | $2.63M derived: sum of 2 quarters · filed 2024-08-06 | $4.06M 10-Q · filed 2023-11-06 | $5.71M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-06-30 | $1.37M 10-Q · filed 2024-08-06 | $2.81M 10-Q · filed 2024-08-06 | $4.46M derived: sum of 3 quarters · filed 2024-08-06 | $6.11M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | $1.44M 10-Q · filed 2024-05-07 | $3.08M derived: sum of 2 quarters · filed 2024-05-07 | $4.73M derived: sum of 3 quarters · filed 2024-05-07 | $6.37M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $3.30M derived: sum of 2 quarters · filed 2024-03-05 | $4.93M derived: sum of 3 quarters · filed 2024-03-05 | $6.55M 10-K · filed 2024-03-05 | |
| 2022-09-30 | $1.65M 10-Q · filed 2023-11-06 | $3.28M derived: sum of 2 quarters · filed 2023-11-06 | $4.90M 10-Q · filed 2023-11-06 | $6.65M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | $1.64M 10-Q · filed 2023-08-07 | $3.25M 10-Q · filed 2023-08-07 | $5.00M derived: sum of 3 quarters · filed 2023-08-07 | $7.78M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-03-31 | $1.62M 10-Q · filed 2023-05-02 | $3.36M derived: sum of 2 quarters · filed 2023-05-02 | $6.15M derived: sum of 3 quarters · filed 2023-05-02 | $8.91M derived: sum of 4 quarters · filed 2023-05-02 | |
| 2021-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $4.53M derived: sum of 2 quarters · filed 2023-03-31 | $7.29M derived: sum of 3 quarters · filed 2023-03-31 | $10.05M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $2.79M 10-Q · filed 2022-11-01 | $5.54M derived: sum of 2 quarters · filed 2022-11-01 | $8.30M 10-Q · filed 2022-11-01 | $11.07M derived: sum of 4 quarters · filed 2022-11-01 | |
| 2021-06-30 | $2.76M 10-Q · filed 2022-08-02 | $5.52M 10-Q · filed 2022-08-02 | $8.29M derived: sum of 3 quarters · filed 2022-08-02 | $11.06M derived: sum of 4 quarters · filed 2022-08-02 | |
| 2021-03-31 | $2.76M 10-Q · filed 2022-05-04 | $5.53M derived: sum of 2 quarters · filed 2022-05-04 | $8.31M derived: sum of 3 quarters · filed 2022-05-04 | $11.05M derived: sum of 4 quarters · filed 2022-05-04 | |
| 2020-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $5.55M derived: sum of 2 quarters · filed 2022-03-08 | $8.29M derived: sum of 3 quarters · filed 2022-03-08 | $11.06M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $2.78M 10-Q · filed 2021-11-02 | $5.53M derived: sum of 2 quarters · filed 2021-11-02 | $8.30M 10-Q · filed 2021-11-02 | $11.10M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2020-06-30 | $2.75M 10-Q · filed 2021-08-03 | $5.52M 10-Q · filed 2021-08-03 | $8.32M derived: sum of 3 quarters · filed 2021-08-03 | $10.97M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2020-03-31 | $2.77M 10-Q · filed 2021-05-04 | $5.57M derived: sum of 2 quarters · filed 2021-05-04 | $8.23M derived: sum of 3 quarters · filed 2021-05-04 | $10.16M derived: sum of 4 quarters · filed 2021-05-04 | |
| 2019-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $5.46M derived: sum of 2 quarters · filed 2021-03-09 | $7.39M derived: sum of 3 quarters · filed 2021-03-09 | $9.32M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $2.65M 10-Q · filed 2020-11-04 | $4.59M derived: sum of 2 quarters · filed 2020-11-04 | $6.51M 10-Q · filed 2020-11-04 | $8.42M derived: sum of 4 quarters · filed 2020-11-04 | |
| 2019-06-30 | $1.94M 10-Q · filed 2020-08-04 | $3.86M 10-Q · filed 2020-08-04 | $5.76M derived: sum of 3 quarters · filed 2020-08-04 | $7.70M derived: sum of 4 quarters · filed 2020-08-04 | |
| 2019-03-31 | $1.93M 10-Q · filed 2020-05-05 | $3.83M derived: sum of 2 quarters · filed 2020-05-05 | $5.76M derived: sum of 3 quarters · filed 2020-05-05 | $7.69M derived: sum of 4 quarters · filed 2020-05-05 | |
| 2018-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $3.83M derived: sum of 2 quarters · filed 2020-03-11 | $5.76M derived: sum of 3 quarters · filed 2020-03-11 | $7.71M 10-K · filed 2020-03-11 | |
| 2018-09-30 | $1.93M 10-Q · filed 2019-11-05 | $3.86M derived: sum of 2 quarters · filed 2019-11-05 | $5.81M 10-Q · filed 2019-11-05 | $7.76M derived: sum of 4 quarters · filed 2019-11-05 | |
| 2018-06-30 | $1.93M 10-Q · filed 2019-08-06 | $3.88M 10-Q · filed 2019-08-06 | $3.85M 10-Q · filed 2018-09-04 | $5.82M derived: sum of 3 quarters · filed 2019-08-06 | $7.79M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $1.93M 10-Q · filed 2019-05-08 | $3.90M derived: sum of 2 quarters · filed 2019-05-08 | $5.87M derived: sum of 3 quarters · filed 2019-05-08 | $7.82M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $3.94M derived: sum of 2 quarters · filed 2019-03-14 | $5.89M derived: sum of 3 quarters · filed 2019-03-14 | $7.71M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $1.97M 10-Q · filed 2018-11-06 | $3.92M derived: sum of 2 quarters · filed 2018-11-06 | $5.74M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $1.95M 10-Q · filed 2018-09-04 | $3.77M 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |